Nikolaus Christian Simon Mezger,Tobias Paul Seraphin,Robert Ballé,Mirko Griesel,Yvonne Walburga Joko-Fru,Lucia Hämmerl,Jana Feuchtner,Biying Liu,Annelle Zietsman,Bakarou Kamaté,Freddy Houéhanou Rodrigue Gnangnon,Franck Gnahatin,Dimitry Moudiongui Mboungou,Mathewos Assefa,Phoebe Mary Amulen,Gladys Chesumbai,Tatenda Chingonzoh,Cesaltina Feirreira Lorenzoni,Anne Korir,Pablo S Carvalho Santos,Jörg Michael Mezger,Haifa Kathrin Al-Ali,Rafael Mikolajczyk,Donald Max Parkin,Ahmedin Jemal,Eva Johanna Kantelhardt
{"title":"NCCN guideline-concordant cancer care in Sub-Saharan Africa A population-based multi-country study of five cancers.","authors":"Nikolaus Christian Simon Mezger,Tobias Paul Seraphin,Robert Ballé,Mirko Griesel,Yvonne Walburga Joko-Fru,Lucia Hämmerl,Jana Feuchtner,Biying Liu,Annelle Zietsman,Bakarou Kamaté,Freddy Houéhanou Rodrigue Gnangnon,Franck Gnahatin,Dimitry Moudiongui Mboungou,Mathewos Assefa,Phoebe Mary Amulen,Gladys Chesumbai,Tatenda Chingonzoh,Cesaltina Feirreira Lorenzoni,Anne Korir,Pablo S Carvalho Santos,Jörg Michael Mezger,Haifa Kathrin Al-Ali,Rafael Mikolajczyk,Donald Max Parkin,Ahmedin Jemal,Eva Johanna Kantelhardt","doi":"10.1093/jnci/djae221","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nTo assess population-based quality of cancer care in Sub-Saharan Africa and to identify specific gaps and joint opportunities, we assessed concordance of diagnostic and treatment with NCCN harmonized guidelines for leading cancer types in 10 countries.\r\n\r\nMETHODS\r\nAdult patients with female breast cancer (BC), cervical cancer (CC), colorectal cancer (CRC), Non-Hodgkin lymphoma (NHL) and prostate cancer (PC) were randomly drawn from 11 population-based cancer registries. Guideline concordance of diagnostics and treatment was assessed using clinical records. In a sub-cohort of 906 patients with potentially curable cancer (stage I-III BC, CC, CRC, PC, aggressive NHL (any stage)) and documentation for >1 month after diagnosis, we estimated factors associated with guideline-concordant treatment or minor deviations (GCT).\r\n\r\nFINDINGS\r\nDiagnostic information as per guidelines was complete for 1030 (31.7%)of 3246 patients included. In the sub-cohort with curable cancer, GCT was documented in 374 (41.3%, corresponding to 11.7% of 3246 included in the population-based cohort): aggressive NHL (59.8%/9.1% population-based), BC (54.5%/19.0%), PC (39.0%/6.1%), CRC (33.9%/9.5%), and CC (27.8%/11.6%). GCT was most frequent in Namibia (73.1% of curable cancer subset/32.8% population-based) and lowest in Kampala, Uganda (13.5%/3.1%). GCT was negatively associated with poor ECOG status, locally advanced stage, origin from low HDI countries, and a diagnosis of CRC or CC.\r\n\r\nINTERPRETATION\r\nQuality of diagnostic workup and treatment showed major deficits, with considerable disparities among countries and cancer types. Improved diagnostic services are necessary to increase the share of curable cancer in SSA. Treatment components within NCCN guidelines synergetic for several cancers should be prioritized.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"291 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnci/djae221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
To assess population-based quality of cancer care in Sub-Saharan Africa and to identify specific gaps and joint opportunities, we assessed concordance of diagnostic and treatment with NCCN harmonized guidelines for leading cancer types in 10 countries.
METHODS
Adult patients with female breast cancer (BC), cervical cancer (CC), colorectal cancer (CRC), Non-Hodgkin lymphoma (NHL) and prostate cancer (PC) were randomly drawn from 11 population-based cancer registries. Guideline concordance of diagnostics and treatment was assessed using clinical records. In a sub-cohort of 906 patients with potentially curable cancer (stage I-III BC, CC, CRC, PC, aggressive NHL (any stage)) and documentation for >1 month after diagnosis, we estimated factors associated with guideline-concordant treatment or minor deviations (GCT).
FINDINGS
Diagnostic information as per guidelines was complete for 1030 (31.7%)of 3246 patients included. In the sub-cohort with curable cancer, GCT was documented in 374 (41.3%, corresponding to 11.7% of 3246 included in the population-based cohort): aggressive NHL (59.8%/9.1% population-based), BC (54.5%/19.0%), PC (39.0%/6.1%), CRC (33.9%/9.5%), and CC (27.8%/11.6%). GCT was most frequent in Namibia (73.1% of curable cancer subset/32.8% population-based) and lowest in Kampala, Uganda (13.5%/3.1%). GCT was negatively associated with poor ECOG status, locally advanced stage, origin from low HDI countries, and a diagnosis of CRC or CC.
INTERPRETATION
Quality of diagnostic workup and treatment showed major deficits, with considerable disparities among countries and cancer types. Improved diagnostic services are necessary to increase the share of curable cancer in SSA. Treatment components within NCCN guidelines synergetic for several cancers should be prioritized.